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and Nonseptic Systemic Inﬂammatory Response Syndrome
By Christelle Marie, Jane Muret, Catherine Fitting, Marie-Reine Losser, Didier Payen, and Jean-Marc Cavaillon
Ex vivo cytokine production by circulating lymphocytes and
monocytesisreducedinpatientswithinfectiousornoninfec-
tious systemic inflammatory response syndrome. Very few
studies have addressed the reactivity of polymorphonuclear
cells (PMN). To analyze further the relative contribution of
systemic inflammatory response syndrome alone or in com-
bination with infection we studied the interleukin-8 (IL-8)
production by PMN isolated from patients who had under-
gone cardiac surgery with cardiopulmonary bypass (CPB)
and patients with sepsis. Cells were activated with either
lipopolysaccharide (LPS) or heat-killed streptococci. Com-
pared with healthy controls, the release of IL-8 by PMN in
both groups of patients was significantly reduced whether
activated by LPS, independently of its concentration and
origin, or by heat-killed streptococci. These observations
suggest that stressful conditions related to inflammation,
independently of infection, rapidly dampened the reactivity
of circulating PMN. We investigated whether the observed
diminished reactivity of PMN might reflect an endotoxin
tolerance phenomenon. Our in vitro experiments with PMN
from healthy controls indicated that PMN could not be
rendered tolerant stricto sensu. However, our data sug-
gested that LPS-induced mediators such as IL-10 may be
responsible for the observed anergy in patients.
r 1998 by The American Society of Hematology.
P
OLYMORPHONUCLEAR neutrophils (PMN) are key
cells in inﬂammatory processes and during sepsis syn-
drome. Their activation is associated with the release of many
inﬂammatory mediators such as eicosanoids, free radicals, and
proteolytic enzymes. Activated neutrophils display an upregu-
lated expression of CD11b and CD351 and bind to endothelial
cells, contributing to vascular endothelium damage.2,3 They
migrate toward tissues where they maintain inﬂammation and
favor organ dysfunction,4-6 which may lead to lethality.7 The
reactivity of neutrophils is modulated by many cytokines.
Pro-inﬂammatory cytokines such as interleukin-1 (IL-1), IL-8,
and tumor necrosis factor (TNF) are potent activators of PMN
functions. The fact that IL-8 is one of the main cytokines
produced by PMN8-10 allows these cells to perpetuate their own
activation within an autocrine loop. Anti-inﬂammatory cyto-
kines play a major role in dampening PMN functions, including
IL-8 production. We and others have shown that IL-10 and, to a
lesser degree, IL-4, IL-13, and transforming growth factor-b
(TGF-b), can repress IL-8 release by activated PMN.11-14
However, the nature of the triggering signal inﬂuences the
capacity of anti-inﬂammatory cytokines to downmodulate cyto-
kine release.14
During the course of inﬂammation, both pro- and anti-
inﬂammatorycytokines,rapidlyreleasedwithexcessiveproduc-
tion, can be detected in the blood compartment15 where they
modulate the reactivity of circulating leukocytes. Indeed, we
have previously shown that monocytes isolated from septic
patients have a reduced capacity to produce IL-1a, IL-1b, IL-6,
and TNF-a upon activation by endotoxins (lipopolysaccharide
[LPS])16 or heat-killed Gram-positive bacteria.17 This observa-
tion has been conﬁrmed by others with whole blood assays of
the above cytokines18,19 and extended to IL-10,20 IL-12, and
interferon-g (IFN-g),21 but not to IL-1 receptor antagonist
(IL-1ra) production.22 These observations probably follow the
events occurring in the blood compartment, and experiments
with whole blood take into account the plasma environment,
which has been shown to play a major role in deactivating
circulating leukocytes.23 However, the source of cytokines
cannot be analyzed in whole blood assays. So far, McCall et al24
have been the only group to our knowledge to investigate the
effect of sepsis on PMN behavior in terms of cytokine
production. They reported a decreased capacity of neutrophils
to produce IL-1b upon stimulation in ex vivo experiments. The
investigators suggested that the observation was linked to the
well-known endotoxin tolerance phenomenon. However, endo-
toxin tolerance is not initiated only by LPS nor is it restricted to
the LPS-responsiveness.25
Because IL-8 is the most abundant cytokine produced by
neutrophils, we were interested in analyzing the capacity of
PMN from septic patients to produce this speciﬁc chemokine. It
was of interest to compare the observable modiﬁcations in
septic patients consecutive to the infectious process itself and
those associated with the inﬂammatory reaction, independently
of any microbial stimulus. Indeed, we had previously shown
that inﬂammation after surgery was sufficient to reduce the
capacity of monocytes to produce TNF-a, IL-1a, and IL-1b.26
For that purpose we investigated a group of patients who had
undergone cardiac surgery associated with cardiopulmonary
bypass (CPB). It is well known that, although surgery itself is an
inﬂammatory process, the extracellular circulation is associated
with an enhanced inﬂammatory reaction as a consequence of
the interaction of blood with bio-materials.27 Finally, we
attempted to mimic some of the events occurring in vivo to ﬁnd
out whether endotoxin and/or IL-10 could be responsible for the
modiﬁcations we observed in both groups of patients.
MATERIALS AND METHODS
Patients. Eleven patients with sepsis syndrome, as deﬁned by Bone
et al,28 were studied upon admission to intensive care units (ICU) or at
initiation of their sepsis syndrome. The study included 9 men and 2
women, the average age being 49 6 5 years (range, 21 to 69 years) and
the mean simpliﬁed acute physiology score II (SAPS II) being 49 6 7.
There were 8 cases of pneumonia, 1 of pelvic abscess, and 2 of
From Unite ´ d’Immuno-Allergie, Institut Pasteur, Paris; and the
Department of Anaesthesia and Intensive Care Medicine, Ho ˆpital
Lariboisie `re, Paris, France.
Submitted October 1, 1997; accepted December 22, 1997.
Address reprint requests to Jean-Marc Cavaillon, DrSc, Unite ´
d’Immuno-Allergie, Institut Pasteur, 28 rue Dr Roux, 75015 Paris,
France.
The publication costs of this article were defrayed in part by page
charge payment. This article must therefore be hereby marked ‘‘adver-
tisement’’ in accordance with 18 U.S.C. section 1734 solely to indicate
this fact.
r 1998 by The American Society of Hematology.
0006-4971/98/9109-0038$3.00/0
Blood, Vol 91, No 9 (May 1), 1998: pp 3439-3446 3439
For personal use only. on October 31, 2014.  by guest    www.bloodjournal.org From peritonitis, including 5 in septic shock. The outcome was survival for 4
patients. The patients’characteristics are given in Table 1.
Nine patients undergoing cardiopulmonary bypass for selective
artery bypass grafting were studied. The study included 8 men and 1
woman, the average age being 68 6 2 years (range, 63 to 74 years).
Anesthesia induction and maintenance was achieved using ﬂunitraz-
epam, sufentanyl, pancuronium bromide, and isoﬂurane. Administra-
tion of heparin before canulation and subsequent neutralization after
bypass with protamine sulfate were performed in a standard fashion.
Normothermic CPB was performed (32.5 6 0.4°C). The mean timing
of aortic clamping was 55 6 2 minutes. Blood sampling was performed
11⁄2 hours after CPB beginning and always before protamine administra-
tion.
Blood of healthy controls were obtained from 18 subjects either from
the blood bank (Fondation Nationale de Transfusion Sanguine) or from
the laboratory. The study included 7 men and 11 women, the average
age being 32 6 2 years (range, 24 to 51 years).
Isolation of human polymorphonuclear cells. Blood was drawn
onto heparin (20 IU/mL) from healthy volunteers or from patients. Ten
volumes of blood was mixed with 2 vol of glucose dextran (3% glucose;
3% dextran T250; Pharmacia, Uppsala, Sweden) and the leukocytes
were recovered after a 40-minute sedimentation at room temperature.29
The leukocytes were then diluted 1:2 in RPMI-1640 medium and
layered on Ficoll-Hypaque (Milieu de Se ´paration des Lymphocytes
[MSL]; Eurobio, Les Ulis, France). The ratio was 2 vol of leukocytes to
1 vol of MSL.After centrifugation for 25 minutes at 15°C and 500g, the
cell pellet was washed and centrifuged once for 5 minutes at 300g.
Contaminating erythrocytes were lysed after a 5-minute incubation of
the cell pellet at 4°C by resuspension in 5 mL of lysis buffer
(NH4Cl 5 8.32 g/L; NaHCO3 5 0.84 g/L; Na4EDTA 5 43.2 mg/L).
Lysis was stopped by adding a large excess of RPMI-1640 medium
(Glutamax; GIBCO Life Technologies, Paisley, UK) and the cells were
washed and centrifuged for 10 minutes at 200g. The viability of
polymorphonuclear cells (PMN) was assessed by counting the cells in
0.1% eosine.Anonspeciﬁc esterase staining was performed to evaluate
the monocyte contamination, which never exceeded 0.5%.
In vitro culture. PMN cells were cultured in RPMI-1640 medium
(Glutamax; GIBCO Life Technologies) supplemented with antibiotics
(penicillin, 100 IU/mL; streptomycin, 100 µg/mL) and 5% heat-
inactivated normal human serum (a pool of sera from healthy volun-
teers). 0.5-mLaliquots of PMN suspension per well were incubated in a
5% CO2 incubator in 24-well multidish plates (Costar, Cambridge, MA)
for 24 hours at 37°C. Stimuli in volumes #10 µL were added at the
beginning of the culture.At the end of the culture, the supernatants were
obtained, centrifuged for 10 minutes at 300g and 15°C, and kept at
220°C before cytokine assessments.
Reagents. Escherichia coli (0111:B4) lipopolysaccharide was pur-
chased from Sigma (St Louis, MO), TNF-a was obtained from Rho ˆne
Poulenc (Vitry/Seine, France), and Neisseria meningitidis LPS was the
generous gift of Dr Martine Caroff (Institut de Biochimie, Orsay,
France). Heat-killed Streptococcus pyogenes group A (A78) was a kind
gift of Dr H. Mu ¨ller-Alouf (Institut Pasteur de Lille). Recombinant
human IL-10 was a generous gift of Dr J.Abrams (DNAX, PaloAlto, CA).
Two-step experiments. PMN (2 3 106 cells/mL) were cultured in
RPMI-1640 medium (Glutamax; GIBCO Life Technologies) supple-
mented with antibiotics and 5% heat-inactivated normal human serum
(complete medium). A 0.5-mL aliquot of PMN suspension per well in
24-well multidish plates was incubated for 24 hours at 37°C in a 5%
CO2 incubator in the presence of different reagents (‘‘pretraitment
period’’). At the end of this preculture period, the supernatants were
obtained and 0.25 mLof fresh complete medium was added to each well
to preserve adherent neutrophils. Supernatants were centrifuged for 10
minutes at 200g and 15°C and kept at 220°C before IL-8 assessment.
The cell pellets were resuspended in 0.25 mLof fresh complete medium
and plated in the same well as during the ﬁrst 24 hours. Then, multidish
plates were incubated at 37°C for an additional 24 hours of culture in the
presence of various activators (‘‘activation period’’). At the end of the
activation period, the supernatants were obtained, centrifuged 10
minutes at 300g and 15°C, and kept at 220°C before IL-8 assessment.
Assessement of cell-associated forms of IL-8 in whole-blood samples.
One milliliter of blood was centrifuged for 10 minutes at 500g. Plasma
was obtained and kept at 220°C before cytokine assessments. The cell
pellet was lysed in 100 µLof lysis buffer (TRAx buffer;T-Cell Sciences,
Inc, Needham, MA) before addition of RPMI-1640 medium to achieve
a 1-mLtotal volume.
Assessement of cell-associated forms of IL-8 in PMN. At the end of
the culture period (2 3 106 PMN/mL), the PMN pellets were lysed by
adding 100 µL of TRAx lysis buffer before adding 100 µL of diluent
buffer and 300 µLof RPMI medium.
Cytokineenzyme-linkedimmunosorbentassay(ELISA). IL-8ELISA
was performed as previously described30 using a monoclonal anti-
human IL-8 antibody obtained by Dr J-C. Mazie ´ (Hybridolab, Institut
Pasteur) and a rabbit polyclonal anti–IL-8 antibody graciously provided
by Dr N.Vita (Sanoﬁ Recherche, Labe `ge, France).The sensitivity of the
ELISA was 3 pg/mL. In collaboration with Dr S. Berthold (DPC
Biermann, Bad Nauheim, Germany) the values obtained with our
ELISA were compared with those obtained for the same samples using
the chemiluminescent quantiﬁcation of IL-8 (IMMULITE; DPC Bier-
mann). A correlation of r 5 .98 (P 5 .0001) was achieved. We ensured
that the TRAx buffer did not interfere with the accuracy of the ELISA.
Apoptosis assay. PMN apoptosis was assessed as the percent of
cells with hypodiploid DNA by using the technique described by
Nicoletti et al.31After 24 or 48 hours of culture of PMN with or without
activators, cells were centrifuged at 200g for 10 minutes and washed in
phosphate-buffered saline (PBS). The cell pellets were gently resus-
pendedinhypotonicﬂuorochromesolution(50µg/mLpropidiumiodide
[PI], 0.1% sodium citrate, 0.1% Triton X-100) and stored at 4°C in the
dark overnight before the ﬂow-cytometric analysis using a FACScan
ﬂow cytometer (Becton Dickinson Immunocytometry System, San
Jose, CA). The red ﬂuorescence of PI in individual nuclei and the
Table 1. Patients’ Characteristics
Patients Age Sex Etiology Bacteria Shock SAPS II Outcome
DIA 55 M Pneumopathy E coli 1 50 Nonsurvival
LEG 69 M Peritonitis E coli 1 E faecalis 1 74 Nonsurvival
PIC 21 M Peritonitis E coli 1 E faecalis 0 21 Survival
COU 67 M Pneumopathy Aspergillus 1 81 Nonsurvival
TRU 65 F Pneumopathy E cloacae 0 43 Nonsurvival
ELK 59 F Pelvis abscess Streptococcus 0 21 Survival
AST 34 M Pneumopathy Staph aureus 1 48 Survival
MEB 50 M Pneumopathy Staph aureus 0 50 Nonsurvival
KHE 60 M Pneumopathy Not found 0 87 Nonsurvival
BEN 24 M Pneumopathy Legionellae 1 22 Nonsurvival
DUB 31 M Pneumopathy H influenzae 1 S pneumoniae 0 38 Survival
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were excluded from acquisition by raising the forward scatter threshold.
Apoptotic nuclei were easily distinguishable from residual debris by the
high size side scatter value due to the condensation of nuclear
chromatin. Ten thousand events were collected and analyzed using the
software Lysis II program.Apoptotic PMN nuclei were distinguished by
their hypodiploid DNAcontent from the diploid DNAcontent of normal
PMN nuclei.
Statistical analysis. Statistical analyses were performed using the
nonparametric Mann-Whitney U-test for comparing data between
healthy controls and patients and the Wilcoxon signed-rank test for the
two-step experiments performed with the PMN from healthy controls.
RESULTS
Circulating and cell-associated IL-8. Levels of circulating
IL-8 were under the detection limit in controls and in all but two
patients undergoing cardiac surgery before cardiopulmonary
bypass (Fig 1), whereas after cardiopulmonary bypass all
patients but two had detectable levels of plasma IL-8. Similarly,
IL-8 was measurable in all but two septic patients. The highest
values were found among septic patients but the mean levels
between post-CPB and sepsis were not signiﬁcantly different.
The pattern was quite different for cell-associated IL-8. We
have previously shown that cell-associated IL-8 assessed in
whole blood is essentially associated with leukocytes whereas
the contribution of red blood cells is limited.32 Naturally
occurring cell-associated IL-8 was detected in healthy controls,
and levels were similar in pre-CPB patients. Post-CPB patients
had signiﬁcantly higher levels than those measured before CPB
(P 5 .015). The levels of cell-associated IL-8 in septic patients
were also higher than in controls as well as higher than in
post-CPB patients (P 5 .007). Although circulating levels of
IL-8 were similar in infectious and noninfectious inﬂammation,
the levels of cell-associated IL-8 were not.
IL-8 production by isolated PMN. We studied the capacity
of isolated circulating PMN to release IL-8 in response to either
0.1 or 1 µg/mL of LPS of two different bacterial origins or
heat-killed streptococci (Fig 2). A signiﬁcant reduction in the
levels of IL-8 produced in response to the different concentra-
tions of LPS from different origins and to heat-killed strepto-
cocci was observed in both groups of patients. Sepsis or
infectious systemic inﬂammatory response syndrome as well as
noninfectious inﬂammation both led to a reduced capacity of
PMN to release IL-8 upon in vitro stimulation. IL-8 production
in patients undergoing cardiac surgery was also tested in a few
patients before the initiation of the cardiopulmonary bypass,
and the levels of released IL-8 were similar to those obtained in
healthy controls (data not shown).
After cell activation, the levels of IL-8 were also analyzed at
the cellular levels, ie, following cell lysis of PMN (Table 2).
There was no difference between the levels of cell-associated
IL-8 in septic and control groups whereas in most cases there
was a signiﬁcant reduction of the levels found in post-CPB
patients.
In vitro modulation of IL-8 production by PMN from healthy
donors. The reduced levels of IL-8 release by PMN isolated
from septic patients or patients who underwent cardiopulmo-
nary bypass could be the consequence of in vivo exposure of
PMN to endotoxin and/or to IL-10. We attempted to mimic this
situation by preculturing PMN from healthy donors in the
presence of LPS, IL-10, or both, before further activation by
LPS. Numerous investigators have reported a high percent of
apoptotic PMN after a 24-hour culture period.33,34 However, our
PMN preparations (dextran 1 glucose sedimentation and a
Ficoll-Hypaque [MSL] step) and our culture conditions in the
presence of normal human serum led to a low percentage of
apoptotic cells after a 24-hour culture period. Recovery of live
cells after an overnight culture period was 89% 6 14% with
15% 6 2% and 9% 6 2% apoptotic cells in the absence or in the
presence of LPS, respectively. After 48 hours the recovery was
46% 6 15% live cells and 35% 6 11% apoptotic cells. Thus, it
was possible to perform the two-step experiments over 48
hours. The mean values of four experiments are shown in Fig 3:
PMN maintained for 24 hours in culture medium alone were
fully responsive to LPS during an additional 24-hour culture
period and release signiﬁcant amounts of IL-8 in a dose-dependent
fashion, illustrating the good viability of the cells. Such IL-8
production (24 to 48 hours) also occurred when the cells had
Fig 1. Measurement of circulating IL-8 in plasma (left) of healthy
controls, patients undergoing cardiac surgery before (pre-CPB), and
after (post-CPB) cardiopulmonary bypass and patients with sepsis.
Cell-associated IL-8 was assessed in whole-blood cell pellet of the
same groups of donors (right). Each symbol represents an individual
subject and the thick short lines represent the median value for each
group.
Fig 2. IL-8 production by isolated polymorphonuclear cells (PMN)
after in vitro activation with LPS from different origins (Escherichia
coli: E.c.; Neisseria meningitidis: N.m.) or with heat-killed, group A
streptococcus. The data are the mean of experiments performed with
isolated PMN from healthy controls (n 5 13), post-CPB patients
(n 5 9), and patients with sepsis (n 5 11). P values correspond to
statistical analysis between post-CPB or sepsis groups versus control
one.
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and then left in cultured medium alone. LPS-pretreated cells
responded in an additional fashion when reexposed to LPS.
Similarly, LPS-pretreated PMN had an enhanced IL-8 produc-
tion upon a further challenge by recombinant human TNF (10
ng/mL) compared with cells maintained for 24 hours in culture
medium alone (8,631 6 3,880 v 3,293 6 925, P 5 .04; mean of
ﬁve experiments). Thus, in contrast to monocytes which upon
preexposure to LPS are ‘‘tolerized’’ and have a lower capacity
to release cytokines,35 PMN were not rendered tolerant to LPS
by prior encounter with LPS. To see whether this effect was
speciﬁc for LPS or could be obtained with other activating
signals, PMN were ﬁrst cultured in the presence of TNF, and
further cultured in the presence of LPS (Table 3). TNF
pretreated PMN continue to release IL-8 once TNF has been
withdrawn. Addition of LPS acted synergistically and led to an
enhanced release of IL-8, while a second TNF stimulation had
an insigniﬁcant enhancing effect.
To further understand the mechanism leading to the PMN
anergy we observed in the patients, we analyzed the effects of
IL-10, known to circulate in these patients.As shown in Fig 4A,
simultaneous addition of IL-10 and LPS led to an 88%
inhibition of IL-8 production by PMN, conﬁrming numerous
previous studies, including ours.11,14 Pretreatment of PMN with
IL-10 render the cells less reactive to a subsequent stimulation
with LPS (P 5 .02) (Fig 4B). Furthermore, pretreatment of
PMN with IL-10 abolished the priming effect of LPS to a
further activation by LPS (P 5 .01).
DISCUSSION
Circulating and cell-associated IL-8. Systemic inﬂamma-
tory response syndrome of infectious (eg, sepsis syndrome) or
noninfectious (eg, cardiopulmonary bypass surgery) origin can
both be associated with the detection of circulating cytokines.
Although the plasma levels of IL-8 could not discriminate
between the two types of inﬂammation, signiﬁcantly higher
levels of cell-associated IL-8 were measured in septic patients
(Fig 1).An enhanced cell-associated IL-8 was found in patients
after cardiac surgery involving CPB as compared to pre-CPB in
agreement with a previous report.36 We have previously shown
that a high proportion of IL-8 in the blood compartment was
associated with erythrocytes and mainly with mononuclear and
polymorphonuclear cells.32 A major proportion of the cell-
associated IL-8 found with leukocytes was the result of
internalization of surrounding IL-8. Because post-CPB and
septic patients had similar levels of circulating PMN (data not
shown), the relative number of circulating cells may have had
little inﬂuence on the lower level of cell-associated IL-8
observed in the CPB group. These results may rather reﬂect
lower IL-8 receptor expression and IL-8 internalization process
in this group of patients. The analysis of cell-associated IL-8
after in vitro activation which led to a diminished level of
PMN-associated IL-8 among CPB patients as compared with
healthy controls (Table 2) further argues for a lower IL-8
receptor expression. Indeed, C5a generated during extracorpo-
ral circulation and IL-8 itself known to modulate IL-8 receptor
expression37,38 may be the causative agents which led to low
IL-8 receptor expression. Further experiments will test it.
Among the septic patients, the reduced levels of IL-8 in PMN
supernatants was not associated with reduced levels of the
Table 2. Levels of PMN-Associated IL-8 (pg/mL) After Ex Vivo Activation
Activators Controls (n 5 13) Sepsis (n 5 10) Post-CPB (n 5 9)
None 3,621 6 1,125 3,056 6 1,121 2,534 6 464
LPS E.c. 0.1 µg/mL 12,133 6 1,681 12,225 6 4,657 6,298 6 740*
1 µg/mL 16,501 6 2,861 18,164 6 5,884 11,263 6 1,181
LPS N.m. 0.1 µg/mL 13,154 6 2,074 14,252 6 5,195 6,222 6 830*
1 µg/mL 19,559 6 3,822 17,589 6 5,852 9,605 6 801*
Streptococcus 107 CFU 11,743 6 1,770 8,231 6 2,252 6,024 6 990*
*P , .05 v control.
Fig 3. In vitro model of tolerization. PMN from healthy donors
were first cultured over 24 hours in the presence or absence of
increasing amounts of E coli LPS. Supernatants were obtained and
fresh medium was added to the cells. PMN were further cultured for
an additional 24 hours (24-48 h) in the presence or absence of
increasing amounts of E coli. IL-8 was measured in the supernatants.
The results are the mean of four different experiments; the mean of
SEM was 630%.
Table 3. Priming Effect of TNF on IL-8 Production
(pg/mL) by Human PMN
0-24 h Culture
24-48 h Culture
None LPS E.c. (1 µg/mL) TNF (10 ng/mL)
None 566 6 83 7,773 6 4,147 3,293 6 925
P 5 .04 NS
TNF (10 ng/mL) 4,237 6 1,954 26,316 6 11,576 5,682 6 3,011
Mean 6 SEM of five different experiments.
Abbreviation: NS, not significant.
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speculate that the receptor-mediated trapping of the IL-8
released by PMN upon activation and its internalization was
achieved with a certain amount of IL-8, a level of which was
reached in both healthy and septic patients.The PMN of healthy
donors do produce more IL-8 than those from septic patients
and the difference could only be found in the PMN superna-
tants.
Sepsis and reduced cytokine production/PMN hyporeactivity.
Whole-blood assays have been widely used these last years to
investigate the capacity of circulating leukocytes to produce
cytokines within their local environment. A reduced capacity
was observed when IL-1,TNF-a, IL-6, IL-10, IL-12, and IFN-g
were investigated.18-22,39,40 We also studied the capacity of
whole-blood samples to generate IL-8 upon in vitro activation.
Low concentrations of endotoxins, independently of their
origin, allow the detection of a diminished capacity to produce
IL-8 in septic patients compared with healthy controls. On the
contrary, when higher amounts of LPS or heat-killed strepto-
cocci were used, no signiﬁcant changes were observed. In CPB
patients the capacity to produce IL-8 was unchanged as
compared to controls (data not shown).
Experiments performed with whole-blood assays give no
information about the speciﬁc reactivity of a given cell lineage.
We have previously investigated the capacity of monocytes
from septic patients to be activated.16,17 Because IL-8 is mainly
produced by both monocytes and neutrophils within the blood
compartment we decided to analyze the PMN reactivity. Indeed,
very few studies have investigated the production of cytokines
by neutrophils from septic patients and we showed that, as
previously reported for IL-1b,24 circulating PMN have a
signiﬁcantly reduced capacity to release IL-8. In contrast to the
data reported on IL-1b, our observation was made indepen-
dently of the nature of the triggering signal. Endotoxins from
various origins used at different concentrations as well as
heat-killed streptococci led to a reduced production of IL-8
compared with healthy subjects.
Although PMN have been claimed to exist in one of three
states (quiescent, primed, or activated),41 it is clear that a fourth
state, ie, deactivated, exists. Indeed, other PMN functions have
been reported to be reduced in infected patients such as the
protein kinase C–dependent stimulation of superoxide produc-
tion.42 In rabbits, in vitro complement (C5)-dependent degranu-
lation of PMN was reduced after intravenous injection of LPS,43
and in human volunteers administration of endotoxin leads to a
markedly reduced ex vivo neutrophil chemotactic activity.44
Accordingly, in in vivo experiments, LPS-pretreated animals
showed a diminished recruitment of PMN into tissues after
local challenge.43,45 Deactivation of PMN has also been re-
ported in noninfectious pathologies. For example, Parsons et
al46 reported that PMN from patients with adult respiratory
distress syndrome (ARDS) produced less superoxide than did
cells from normal subjects when primed with LPS and stimu-
lated with formyl-methionyl-leucine-phenylalanine. However,
not all PMN functions may be altered during inﬂammation
and/or infection because H2O2 generation was shown to be
enhanced in septic patients47 and in a PMN subpopulation from
ARDS patients.48
Inﬂammatory stress and ex vivo cytokine production. To see
whether the reduced IL-8 production by PMN we observed in
septic patients was speciﬁc to an infectious process or related to
the systemic inﬂammatory response, we included another group
of patients who underwent cardiac surgery associated with
cardiopulmonary bypass. Inﬂammatory stress that occurs dur-
ing CPB is linked to the surgical procedure itself as well as to
the interaction of circulating leukocytes with biomaterials
during extracorporal circulation.27 To our knowledge, very few
investigators have tested the ex vivo capacity of leukocytes of
CPB patients to release cytokine upon activation. Naldini et al49
have reported that phytohemagglutinin-induced production of
IFN-g, IL-2, and TNF by peripheral blood mononuclear cells
were signiﬁcantly diminished while IL-1b, IL-6, and IL-8 were
not affected. In addition, we have previously shown that surgery
itself leads to a reduced capacity of monocytes to release IL-1a,
IL-1b, and TNF-a, but not IL-6.26 Other stressful conditions
such as trauma,21,50,51 thermal injury,52 and hemorrhage53 are
also associated with a reduced capacity of leukocytes to
produce cytokine upon cell stimulation. We observed that IL-8
production by PMN as well as IL-10 production by peripheral
blood mononuclear cells (manuscript submitted) were signiﬁ-
cantly reduced in CPB patients. In addition to the inﬂammatory
stress, other parameters such as some drugs may affect cytokine
production by circulating leukocytes. Among the drugs used in
the patients, aprotinin, a serine protease inhibitor, has been
shown to reduce IL-8 levels in broncho-alveolar lavages of
patients after CPB.54We have performed experiments by adding
aprotinin to whole blood of healthy controls at concentrations
similar to those generated in the patients’blood (500 KIU/mL).
Blood was maintained at 37°C for 3 hours before performing
the PMN preparation, similarly to the in vivo situation before
Fig 4. In vitro model of tolerization. PMN from healthy donors
were first cultured over 24 hours in the presence or absence of either
E coli LPS (100 ng/mL) or recombinant human IL-10 (10 ng/mL) or
both. Supernatants were obtained and IL-8 was measured (A). Fresh
medium was added to the cells and the PMN were further cultured for
an additional 24-hour period (24-48 h) in the presence or absence of E
coli LPS (1 mg/mL). IL-8 was measured in the supernatants (B). The
results are the mean of eight different experiments. (b v a: P 5 .01; c v
a: P 5 .02; d v a: P 5 .01; d v b: P 5 .01.)
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activation by either LPS or streptoccoci, an enhanced release of
IL-8 was observed (49% 6 9%) (data not shown), just at the
opposite of the ex vivo observation. This observation indicates
that aprotinin is not the causative agent of the decreased IL-8
production observed in CPB patients. This does not mean that
other drugs such as those used for anesthesia do not interfere in
the ability of PMN to produce IL-8. However, in a preliminary
study on four patients undergoing prolonged anesthesia with a
light surgical stress (arterial embolization for aneurysm), we did
not observe any signiﬁcant modiﬁcation of the IL-8 production
by isolated PMN upon activation.
The presence of circulating pro- and anti-inﬂammatory
cytokines such as IL-6,55 IL-8,55,56 TNF,57 IL-10,58 TGF-b,59 as
well as the induction of cell-associated IL-160 in patients
undergoing CPB, conﬁrms that a systemic inﬂammatory pro-
cess does occur. Thus, a rapid deactivation of circulating PMN
in terms of IL-8 production was observed in CPB patients,
suggesting that the inﬂammatory component of sepsis syn-
drome may be sufficient to alter the IL-8 synthesis machinery in
PMN. Although CPB is not associated with infectious pro-
cesses, circulating LPS has been detected in these patients61
and, as in infected patients, its role in affecting PMN reactivity
could be considered as endotoxin tolerance.25
In vitro tolerization of PMN from healthy donors. To
determine whether an LPS encounter in vivo in patients could
alter PMN reactivity to a later in vitro LPS stimulation, we
performed two-step experiments with PMN prepared from
healthy controls. PMN were ﬁrst stimulated with LPS overnight
and resuspended in fresh medium in the presence of activating
LPS for another 24-hour culture. IL-8 production was then
assessed in the cell supernatants.Although a high percentage of
PMN has been reported to become rapidly apoptotic in cul-
tures,33,34 our culture conditions had a low level of apoptotic cell
after 24 hours and allowed us to perform these two-step
analyses. Although a similar protocol led to tolerized mono-
cytes,35,62 neutrophils that were ﬁrst exposed to LPS before a
secondary stimulation with LPS had an enhanced cytokine
production.
In monocytes, IL-10 could mimic in vitro LPS tolerization,35
and septic63 as well as CPB58 patients have circulating IL-10.
So, it was worthwhile to see whether pretreatment of PMN by
IL-10 led to a reduction of IL-8 production. As previously
reported,11,14 IL-10 is a potent inhibitor of IL-8 production by
PMN when added simultaneously with LPS. The effect of
pretreatment of PMN by IL-10 led to a signiﬁcant reduction of
subsequent LPS-induced IL-8 production. Furthermore, when
IL-10 and LPS were added simultaneously during the pretreat-
ment period, IL-10 completely obliterated the ‘‘priming’’effects
of LPS. Thus, while PMN can be rendered less reactive to a
secondary stimulation by LPS after pretreatment with IL-10,
they cannot be rendered tolerant to endotoxin stricto sensu by
LPS itself. McCall et al24 claimed that PMN from septic patients
were endotoxin tolerant. However, this statement should be
reconsidered very carefully. Although there are many earlier
reports that PMN could be primed by a short preexposure to
LPS for enhanced release of oxygen metabolites64 and for the
synthesis of 5-lipoxygenase products65 there was no long
exposure of PMN and, to our knowledge, this is the ﬁrst
demonstration of a priming effect of LPS on IL-8 production.A
similar priming effect was noticed after a ﬁrst encounter of
PMN with TNF. These results obtained after a ﬁrst activation of
long duration are in contrast with a previous report66 in which a
2-hour pretreatment with low amounts of TNF led to deacti-
vated PMN with reduced transcobalamine release and burst
activity in response to TNF. In this report, in contrast to most
other reports, a 2-hour pretreatment with LPS also led to a
deactivation of PMN when further challenged with TNF.
We have focused our attention on the responsiveness of
isolated neutrophils from patients with systemic inﬂammatory
response syndrome of infectious or noninfectious origin. In
both cases the release of IL-8 upon activation by endotoxins or
heat-killed streptococci was signiﬁcantly reduced, suggesting
that stressful conditions rapidly dampen the reactivity of
circulating PMN. As suggested by in vitro experiments per-
formed with PMN from healthy controls, the observed phenom-
enon does not reﬂect an endotoxin tolerance phenomenon
stricto sensu because LPS was unable to desensitize the cells to
a second challenge by LPS as reported for monocytes. Our in
vitro results suggest that LPS-induced mediators such as IL-10
may be responsible for the observed anergy in patients.
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